Raloxifene vs Sitagliptin: side-by-side comparison
Raloxifene (Selective estrogen receptor modulator (SERM)) and Sitagliptin (DPP-4 inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Raloxifene | Sitagliptin |
|---|---|---|
| Therapeutic class | Selective estrogen receptor modulator (SERM) | DPP-4 inhibitor |
| CAS | 84449-90-1 | 486460-32-6 |
| ATC | G03XC01 | A10BH01 |
| Molecular weight | 473.59 g/mol | 407.31 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Raloxifene and Sitagliptin share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Raloxifene acts by a different mechanism than Sitagliptin, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Raloxifene: Raloxifene binds estrogen receptors and produces tissue-selective effects: estrogen-agonist activity in bone (preserving bone mineral density) and on lipid metabolism (lowering LDL cholesterol), while exhibiting estrogen… Sitagliptin: Sitagliptin reversibly inhibits DPP-4, the serine protease responsible for rapid degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Indications compared
Raloxifene: Raloxifene is approved for prevention and treatment of postmenopausal osteoporosis, and for reduction of invasive breast cancer risk in postmenopausal women at increased risk. Sitagliptin: Sitagliptin is approved in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control.
Safety profile
Raloxifene: Common adverse effects include hot flashes (paradoxically common because raloxifene is a partial estrogen agonist/antagonist), leg cramps and peripheral oedema. Sitagliptin: Sitagliptin is generally well tolerated.
Frequently asked questions
Is Raloxifene better than Sitagliptin? ▾
Raloxifene and Sitagliptin are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Raloxifene and Sitagliptin be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Raloxifene
Products with Sitagliptin
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.